Cloudbreak Pharma Schedules 31 Aug 2026 Board Meeting to Review H1 2026 Results and Interim Dividend

Bulletin Express

Aug 19

Cloudbreak Pharma Inc. has announced that its board of directors will convene on 31 August 2026 to review and approve the Group’s unaudited interim results for the six months ended 30 June 2026. The agenda also includes deliberation on a possible interim dividend.

The meeting will be chaired by Dr. Ni Jinsong, who serves as Chairman, Executive Director and Chief Executive Officer. The current Board comprises nine members: three executive directors (Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong), three non-executive directors (Dr. Li Jun Zhi, Mr. Cao Xu, Mr. Xia Zhidong) and three independent non-executive directors (Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang).

No financial figures were disclosed in the announcement; full details are expected upon publication of the interim results following the scheduled meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1130257316"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1130257316\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1130257316?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-19 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1130257316","market":"us","top_or_hot":-1,"title":"Cloudbreak Pharma Schedules 31 Aug 2026 Board Meeting to Review H1 2026 Results and Interim Dividend","media":"Bulletin Express","content":"<p>Cloudbreak Pharma Inc. has announced that its board of directors will convene on 31 August 2026 to review and approve the Group’s unaudited interim results for the six months ended 30 June 2026. The agenda also includes deliberation on a possible interim dividend.</p>\n<p>The meeting will be chaired by Dr. Ni Jinsong, who serves as Chairman, Executive Director and Chief Executive Officer. The current Board comprises nine members: three executive directors (Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong), three non-executive directors (Dr. Li Jun Zhi, Mr. Cao Xu, Mr. Xia Zhidong) and three independent non-executive directors (Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang).</p>\n<p>No financial figures were disclosed in the announcement; full details are expected upon publication of the interim results following the scheduled meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cloudbreak Pharma Schedules 31 Aug 2026 Board Meeting to Review H1 2026 Results and Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCloudbreak Pharma Schedules 31 Aug 2026 Board Meeting to Review H1 2026 Results and Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-19 22:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Cloudbreak Pharma Inc. has announced that its board of directors will convene on 31 August 2026 to review and approve the Group’s unaudited interim results for the six months ended 30 June 2026. The agenda also includes deliberation on a possible interim dividend.</p>\n<p>The meeting will be chaired by Dr. Ni Jinsong, who serves as Chairman, Executive Director and Chief Executive Officer. The current Board comprises nine members: three executive directors (Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong), three non-executive directors (Dr. Li Jun Zhi, Mr. Cao Xu, Mr. Xia Zhidong) and three independent non-executive directors (Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang).</p>\n<p>No financial figures were disclosed in the announcement; full details are expected upon publication of the interim results following the scheduled meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02592","symbol_name":"拨康视云-B","start_time":0,"source_url":"","article_id":"1130257316","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1130257316","pubTimestamp":1787149739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Cloudbreak Pharma Inc. has announced that its board of directors will convene on 31 August 2026 to review and approve the Group’s unaudited interim results for the six months ended 30 June 2026. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02592":"拨康视云-B"},"translate_title":"Cloudbreak Pharma 计划于 2026 年 8 月 31 日召开董事会会议，审查 2026 年上半年业绩和中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1},"content_text":"Cloudbreak Pharma Inc. has announced that its board of directors will convene on 31 August 2026 to review and approve the Group’s unaudited interim results for the six months ended 30 June 2026. The agenda also includes deliberation on a possible interim dividend.\nThe meeting will be chaired by Dr. Ni Jinsong, who serves as Chairman, Executive Director and Chief Executive Officer. The current Board comprises nine members: three executive directors (Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong), three non-executive directors (Dr. Li Jun Zhi, Mr. Cao Xu, Mr. Xia Zhidong) and three independent non-executive directors (Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang).\nNo financial figures were disclosed in the announcement; full details are expected upon publication of the interim results following the scheduled meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}